10,000th Patient in the United States Treated With Transoral Incisionless Fundoplication (TIF®) Using EsophyX® Technology From EndoGastric Solutions, Inc.

REDWOOD CITY, Calif.--(BUSINESS WIRE)--EndoGastric Solutions® (EGS), the leader in the endoluminal treatment of Gastroesophageal Reflux Disease (GERD), today announced more than 10,000 patients in the U.S. have been treated with the TIF procedure using the company’s EsophyX® device. GERD is a chronic disease that affects over 60 million people in the U.S.